Castle Biosciences, Inc. Common Stock (CSTL) Stock Price
CSTLStock
$31.96+41.86%52W
Market Cap$976.36M
P/E47.31x
PEG Ratio—
Div yield—
Beta1.00
CSTL Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)21.24%
Price vs S&P 500 (4W)-7.33%
VGM Score58.18
P/E Ratio (Annual)47.31x
CSTL Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q2 2026 | -$0.41 | -$0.07 | +82.79%(+$0.34) | |
| Q1 2026 | -$0.49 | -$0.49 | -0.26%(-$0.00) | |
| Q4 2025 | -$0.26 | -$0.08 | +69.08%(+$0.18) | |
| Q3 2025 | -$0.51 | -$0.02 | +96.08%(+$0.49) | |
| Q2 2025 | -$0.50 | $0.15 | +130.00%(+$0.65) |
CSTL Analyst Recommendations
Jun 2026
Jul 2026
Aug 2026
Sep 2026
4.43
4.40
4.40
4.40
Industry Peers — Health Services(30)
| Symbol | Value Score | Growth Score | Momentum Score | P/E Ratio (Annual) | Revenue Growth TTM (YoY) | Operating Margin (TTM) | ROE (TTM) | Price |
|---|---|---|---|---|---|---|---|---|
CSTLCastle Biosciences, Inc. Common Stock | D | B | B | 47.3x | 3.2% | -9.0% | -4.2% | $31.96 |
| NTRANatera, Inc. Common Stock | F | A | A | — | 37.8% | -10.7% | -11.7% | $393.44 |
| DGXQuest Diagnostics Inc. | C | D | B | 26.1x | 9.9% | 14.1% | 14.5% | $235.00 |
| LHLabcorp Holdings Inc. | C | D | B | 29.4x | 6.4% | 10.4% | 11.6% | $317.95 |
| GHGuardant Health, Inc. Common Stock | F | A | B | — | 42.7% | -40.2% | -246.6% | $158.60 |
| CAICaris Life Sciences, Inc. Common Stock | F | A | B | — | 38.5% | 12.7% | 18.8% | $30.56 |
| RDNTRadNet, Inc. Common Stock | D | C | C | 1779.3x | 18.9% | 3.0% | -1.9% | $68.80 |
| GRALGRAIL, Inc. Common Stock | D | B | B | — | 23.1% | -338.4% | -15.9% | $117.81 |
| BLLNBillionToOne, Inc. Class A Common Stock | F | F | C | 621.1x | — | 10.9% | 8.9% | $98.12 |
| VCYTVeracyte, Inc. | D | B | C | 52.2x | 17.3% | 19.6% | 8.6% | $43.12 |
| CDNACareDx, Inc. | D | B | A | 18.3x | 34.4% | 23.6% | 32.8% | $64.00 |
About Castle Biosciences, Inc. Common Stock
Castle Biosciences is a molecular diagnostics company specializing in gene expression profile tests for oncology and gastrointestinal conditions. Its product portfolio includes DecisionDx-Melanoma and DecisionDx-SCC for skin cancer risk assessment, MyPath Melanoma for melanoma diagnosis, and TissueCypher for monitoring esophageal cancer progression. The company generates revenue by delivering diagnostic test reports to healthcare providers treating patients with dermatologic cancers, uveal melanoma, and Barrett's esophagus.